Krishna Institute of Medical Sciences Ltd

Net profit of Krishna Institute of Medical Sciences declined 37.71% to Rs 66.90 crore in the quarter ended September 2025 as against Rs 107.40 crore during the previous quarter ended September 2024. Sales rose 23.59% to Rs 960.70 crore in the quarter ended September 2025 as against Rs 777.30 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales960.70777.30 24 OPM %21.2328.06 - PBDT163.20203.20 -20 PBT97.10162.20 -40 NP66.90107.40 -38 Powered by Capital Market - Live

Krishna Institute of Medical Sci. will hold a meeting of the Board of Directors of the Company on 7 November 2025.Powered by Capital Market - Live

KIMS Hospital Bengaluru, a wholly owned subsidiary of  Krishna Institute of Medical Science, has formally commenced operations at its newly established hospital located in Mahadevapura, Bengaluru. The state-of-the-art facility is a 450-bedded, multi-specialty tertiary care hospital, designed to provide comprehensive medical services across a wide range of specialties. The hospital is equipped with over 35 medical and surgical specialties, 120+ advanced ICU beds, and more than 100 dedicated OPD (Outpatient Department) beds, catering to both critical and routine healthcare needs. Powered by Capital Market - Live

Net profit of Krishna Institute of Medical Sciences declined 9.24% to Rs 78.60 crore in the quarter ended June 2025 as against Rs 86.60 crore during the previous quarter ended June 2024. Sales rose 26.61% to Rs 871.60 crore in the quarter ended June 2025 as against Rs 688.40 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales871.60688.40 27 OPM %22.1026.06 - PBDT167.10166.10 1 PBT113.70127.10 -11 NP78.6086.60 -9 Powered by Capital Market - Live

Krishna Institute of Medical Sci. will hold a meeting of the Board of Directors of the Company on 6 August 2025.Powered by Capital Market - Live

Krishna Institute of Medical Sci. announced that the 23th Annual General Meeting(AGM) of the company will be held on 29 August 2025.Powered by Capital Market - Live

Net profit of Krishna Institute of Medical Sciences rose 55.42% to Rs 101.80 crore in the quarter ended March 2025 as against Rs 65.50 crore during the previous quarter ended March 2024. Sales rose 25.73% to Rs 796.90 crore in the quarter ended March 2025 as against Rs 633.80 crore during the previous quarter ended March 2024. For the full year,net profit rose 24.03% to Rs 384.50 crore in the year ended March 2025 as against Rs 310.00 crore during the previous year ended March 2024. Sales rose 21.49% to Rs 3035.10 crore in the year ended March 2025 as against Rs 2498.20 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales796.90633.80 26 3035.102498.20 21 OPM %24.8525.07 -25.7925.49 - PBDT175.80146.30 20 724.50606.00 20 PBT123.20100.00 23 547.30459.50 19 NP101.8065.50 55 384.50310.00 24 Powered by Capital Market - Live

Krishna Institute of Medical Sci. will hold a meeting of the Board of Directors of the Company on 12 May 2025.Powered by Capital Market - Live

Krishna Institute of Medical Sciences Ltd fell 7.65% today to trade at Rs 480.7. The BSE Healthcare index is down 0.22% to quote at 38128.73. The index is down 8.88 % over last one month. Among the other constituents of the index, Suven Pharmaceuticals Ltd decreased 4.41% and NGL Fine Chem Ltd lost 4.32% on the day. The BSE Healthcare index went up 9.06 % over last one year compared to the 0.3% fall in benchmark SENSEX. Krishna Institute of Medical Sciences Ltd has lost 21.82% over last one month compared to 8.88% fall in BSE Healthcare index and 5.06% drop in the SENSEX. On the BSE, 6380 shares were traded in the counter so far compared with average daily volumes of 21151 shares in the past one month. The stock hit a record high of Rs 674 on 13 Jan 2025. The stock hit a 52-week low of Rs 350.02 on 04 Jun 2024.Powered by Capital Market - Live

The agreement is for an initial term of 7 years with an extension for a further period of 3 years on an exclusive basis. According to the terms and conditions under of this agreement, KIMS would run, manage, operate, direct and control the hospital and provide the medical services at the hospital. Splendid Hospitals is in the process of constructing a 150-bed hospital, under the name Splendid Hospital, with a total floor area of 1,60,000 square feet. The hospital has the potential due to the location and demand for hospital services and has the capacity to expand to over 200 beds and will be equipped with the latest medical infrastructure, medical and diagnostic equipment, and multiple operation theatres. The hospital is expected to commence operations in June 2025. To ensure the hospital operates efficiently and effectively, Splendid requires the services of a specialized and professional team of experts. Therefore, under the proposed O&M terms, Splendid intends to engage KIMS as the exclusive operator to manage, run, operate, direct, and control the hospital operations, and to provide or facilitate the provision of the medical services as outlined in the relevant schedule of the agreement. In consideration for the medical services fees and in accordance with the terms of this Agreement, KIMS is entitled to receive revenue fee of 9% (nine percent) of the total net revenue. Headquartered in Hyderabad, Krishna Institute of Medical Sciences (KIMS Hospitals) is one of the largest corporate healthcare groups in Telangana, Andhra Pradesh and Mahrashtra, providing multi-disciplinary integrated healthcare services, with a focus on tertiary and quaternary healthcare at affordable cost. The company's consolidated net profit jumped 23.5% to Rs 88.70 crore in Q3 FY25 as compared with Rs 71.84 crore in Q3 FY24. Net sales increased 27.5% YoY to Rs 772.40 crore in Q3 FY25. Powered by Capital Market - Live